Cart
sales@molnova.com
Balamapimod
CAS No. 863029-99-6
Balamapimod( MKI-833 | MKI833 )
Catalog No. M16245 CAS No. 863029-99-6
Balamapimod (MKI-833) is an orally active, reversible Ras/Raf/MEK inhibitor developed for antineoplastic potential.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 873 | Get Quote |
|
| 50MG | 1782 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBalamapimod
-
NoteResearch use only, not for human use.
-
Brief DescriptionBalamapimod (MKI-833) is an orally active, reversible Ras/Raf/MEK inhibitor developed for antineoplastic potential.
-
DescriptionBalamapimod (MKI-833) is an orally active, reversible Ras/Raf/MEK inhibitor developed for antineoplastic potential.
-
In Vitro——
-
In Vivo——
-
SynonymsMKI-833 | MKI833
-
PathwayMAPK/ERK Signaling
-
TargetRaf
-
RecptorRaf
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number863029-99-6
-
Formula Weight574.144
-
Molecular FormulaC30H32ClN7OS
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN#CC1=C(NC2=CC=C(SC3=NC=CN3C)C(Cl)=C2)C4=CC(OC)=C(N5CCC(N6CCCC6)CC5)C=C4N=C1
-
Chemical Name4-[[3-Chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]amino]-6-methoxy-7-[4-(1-pyrrolidinyl)-1-piperidinyl]-3-quinolinecarbonitrile
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
MRTX0902
MRTX0902 is an effective and high selective inhibitor of SOS1 with an IC50 of 46 nM and a Ki of 2 nM.
-
Locostatin
Locostatin is a potent and cell permeable inhibitor of Raf kinase inhibitor protein (RKIP)/Raf1 kinase interaction and an inhibitor of cell migration.Locostatin treatment resulted in the activation of the mitogen-activated protein kinase (MAPK) signal pathway (ERK phosphorylation), providing a powerful validation of our targeting protocol.?
-
GNE-9815
GNE-9815 is a high kinase-selective inhibitor of RAF and targets KRAS-mutant cancers through combination therapy.
